Natrecor is a drug owned by Scios Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 19, 2014. Details of Natrecor's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5114923 | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
May, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Natrecor is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Natrecor's family patents as well as insights into ongoing legal events on those patents.
Natrecor's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Natrecor's generic launch date based on the expiry of its last outstanding patent is estimated to be May 19, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Natrecor Generics:
There are no approved generic versions for Natrecor as of now.
About Natrecor
Natrecor is a drug owned by Scios Llc. It is used for promoting sodium and fluid excretion and increasing blood vessel relaxation. Natrecor uses Nesiritide as an active ingredient. Natrecor was launched by Scios Llc in 2001.
Approval Date:
Natrecor was approved by FDA for market use on 10 August, 2001.
Active Ingredient:
Natrecor uses Nesiritide as the active ingredient. Check out other Drugs and Companies using Nesiritide ingredient
Treatment:
Natrecor is used for promoting sodium and fluid excretion and increasing blood vessel relaxation.
Dosage:
Natrecor is available in for solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | FOR SOLUTION | Discontinued | INTRAVENOUS |